Over-the-Counter Medicines
Cozoltec Tab.
- Product Category
- Antihistamines
- Active Ingredients
- Cetirizine hydrochloride
- Appearance
- A white, oblong, film-coated tablet.
01 / 02
1. Composition and Strength
- Active ingredient: Cetirizine hydrochloride (EP) ---- 10mg
- Additives (animal-derived ingredients): milk hydrate (cow, milk)
- Other additives: titanium oxide, magnesium stearate, low-substituted hydroxypropyl cellulose, colloidal silicon oxide, croscarmellose sodium, talc, propylene glycol, hydroxypropyl cellulose, hypromellose 2910
2. Effectiveness
1. Seasonal and perennial allergic rhinitis (rhinitis), allergic conjunctivitis, chronic idiopathic (unknown cause) urticaria, skin pruritus (itching)
2. Eczema, dermatitis (combined use with hydrocortisone topical medication)
3. Dosage and dosage
1. Adults and children over 6 years old: Cetirizine hydrochloride, administered orally at 10 mg once a day before bedtime.
2. For patients sensitive to adverse reactions, administer 5 mg in divided doses in the morning and evening.
3. Increase or decrease appropriately depending on age and symptoms.
4. Patients with renal impairment: The administration interval should be adjusted according to the patient's renal function. Adjust the dosage by referring to the following table. To use this dosage table, you need the creatinine clearance (CLcr) in mL/min. CLcr (mL/min) is calculated from serum creatinine (mg/dL) measurements using the formula:
: CLcr = [140 - age (age) (years)] x weight (kg) / 72 x serum creatinine (mg/dL) (x0.85 for women)
<Dosage adjustment for adult patients with impaired renal function>
※ Please check the attached document for details.
For pediatric patients with renal impairment (renal impairment), the dose should be adjusted individually, taking into account the patient's renal clearance and body weight.
4. Precautions for use
1. The following people should not take (use) this medicine:
1) Patients with a history of hypersensitivity to this drug and hydroxyzine or piperazine derivatives
2) Patients with renal failure (creatinine clearance < 10mL/min)
3) Pregnant women, women who may be pregnant, or lactating women
4) Infants under 6 years of age
5) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. (Limited to products containing lactose)
2. Do not take (use) the following medicines while taking (using) this medicine.
1) In a multiple-dose study of theophylline (400 mg once daily) and cetirizine, the pharmacokinetics of theophylline did not change when administered together with cetirizine, while the clearance of cetirizine decreased slightly (16%).
2) In a multiple-dose study of ritonavir (600 mg, twice daily) and cetirizine (10 mg daily), the breakdown of ritonavir was slightly changed (-11%) when administered together with cetirizine, while the exposure to cetirizine increased by approximately 40%.
3. Do not do the following while taking (using) this medicine.
1) As this drug is secreted in small amounts through breast milk, breast-feeding should be discontinued during administration.
2) As with other antihistamines, do not administer with excessive amounts of alcohol.
4. The following people should consult a doctor, dentist, or pharmacist before taking (using) this medicine.
1) Patients with renal impairment (high blood levels may persist)
2) Patients with hepatic impairment (high blood levels may persist)
3) Elderly (high blood levels may persist)
This drug is mainly excreted through the kidneys, so in elderly people with reduced renal function, excessive blood concentration may persist. Therefore, start administration with caution at a low dose, and if abnormalities are recognized, reduce the dose or stop taking the drug and take appropriate measures.
4) Epilepsy patients and patients at risk of seizures
5) This drug may increase the risk of urinary retention, so caution should be exercised when using it in patients with predisposing factors for urinary retention (e.g. spinal cord lesions, prostatic hyperplasia).
5. In the following cases, immediately stop taking (using) this drug and consult a doctor, dentist, or pharmacist. Please carry this attached document with you whenever possible during consultation.
1) Symptoms and treatment in case of overdose
- Symptoms: Symptoms observed after overdose of cetirizine are mainly related to central nervous system effects or effects considered to be anticholinergic. Adverse reactions reported after taking at least 5 times the recommended daily dose include: confusion, diarrhea, dizziness, fatigue, headache, malaise, dilated pupils, itching, nervousness, sedation, drowsiness, stupor, tachycardia, tremors, and urine retention.
- Treatment: There is no known specific antidote for cetirizine. If an overdose of this drug is administered, symptomatic treatment or supportive treatment is recommended. If it has only recently been taken, gastric lavage should be considered.
Cetirizine is not effectively removed by dialysis.
2) Mental nervous system: Drowsiness, headache, sometimes malaise, paralysis, asthenia, nervousness, paresthesia, rarely mild and temporary drowsiness, fatigue, dizziness, heaviness in the head, excitement, convulsions, dyskinesia, dystonia, syncope, tremors, aggression, confusion, depression, hallucinations, insomnia, tic disorder, amnesia, memory impairment, suicidal ideation, and nightmares may occur.
3) Digestive system: Sometimes thirst, dry lips, nausea, loss of appetite, stomach discomfort, indigestion, abdominal pain, stomach pain, abdominal discomfort, diarrhea, rarely vomiting, gastrointestinal disorders, cheilitis, abnormal taste, and increased appetite may occur.
4) Circulatory system: In rare cases, rapid pulse, arrhythmia, increased blood pressure, and sometimes palpitations may occur.
5) Blood: Vasculitis, sometimes a decrease in white blood cells, a decrease in neutrophils, an increase in lymphocytes, an increase in eosinophils, rarely an increase in monocytes, and an increase in platelets may occur. In addition, since thrombocytopenia may rarely occur, sufficient observation should be conducted, and if abnormalities are recognized, administration should be discontinued and appropriate measures should be taken.
6) Immune system, skin and subcutaneous tissue: Photosensitivity, rarely hypersensitivity and anaphylactic shock, sometimes swelling, itching, rash, rarely urticaria, angioneurotic edema, fixed drug rash, and acute generalized rash and pustulosis may occur.
7) Eyes: In rare cases, blurred vision, conjunctival injection, ocular control disorders, and anterior-posterior eye movements (oculogyration) may occur.
8) Ear and Maze: Vertigo
9) Liver: Occasionally, liver dysfunction such as elevation of AST, ALT, ALP, total bilirubin, γ-GTP, LDH, etc. (early symptoms: general malaise, loss of appetite, fever, nausea, etc.), jaundice, and hepatitis may occur. Therefore, observe thoroughly, and if abnormalities are recognized, discontinue administration and take appropriate measures.
10) Kidney: Occasionally, BUN elevation, diabetes, bloody urine, rare urination difficulties, enuresis, and urine retention may occur.
11) Musculoskeletal and connective tissue disorders: joint pain
12) Others: Pharyngitis, cough, nosebleeds, bronchospasm, hearing abnormalities, visual abnormalities, sometimes chest pain, rarely menstrual irregularities, tinnitus, rhinitis, and weight gain may occur.
13) After cetirizine treatment was discontinued, itching and/or hives were reported in some patients.
6. Other precautions when taking (using) this drug
1) Since this drug inhibits the intradermal reaction to allergens, it is advisable not to administer this drug 3 to 5 days before conducting an allergen intradermal reaction test.
2) As a result of administering 20 to 25 mg per day to healthy volunteers, no side effects were observed in agility or reaction time, but the dose was not exceeded when driving or operating machinery. Although the racemate (enantiomer) does not appear to increase the effects of alcohol (0.5 g/L blood level), coadministration of alcohol or other CNS depressants may further reduce alertness and cause performance impairment.
3) Depending on the symptoms, if there is no improvement with the administration of 10 mg of this drug per day, there are clinical reports of administering up to 20 mg per day according to the instructions of a doctor or pharmacist.
4) The absorption rate of cetirizine is reduced by food for about 1 hour, but the degree of absorption is not reduced.
7. Storage precautions
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause an accident due to incorrect use of the medicine or cause a decrease in the quality of the medicine, so put it in the original container and keep it tightly closed.
5. How to save
Airtight container, stored at room temperature (1∼30℃)
6. Packaging unit
10 tablets/PTP
7. Validity period
36 months from date of manufacture
- Active ingredient: Cetirizine hydrochloride (EP) ---- 10mg
- Additives (animal-derived ingredients): milk hydrate (cow, milk)
- Other additives: titanium oxide, magnesium stearate, low-substituted hydroxypropyl cellulose, colloidal silicon oxide, croscarmellose sodium, talc, propylene glycol, hydroxypropyl cellulose, hypromellose 2910
2. Effectiveness
1. Seasonal and perennial allergic rhinitis (rhinitis), allergic conjunctivitis, chronic idiopathic (unknown cause) urticaria, skin pruritus (itching)
2. Eczema, dermatitis (combined use with hydrocortisone topical medication)
3. Dosage and dosage
1. Adults and children over 6 years old: Cetirizine hydrochloride, administered orally at 10 mg once a day before bedtime.
2. For patients sensitive to adverse reactions, administer 5 mg in divided doses in the morning and evening.
3. Increase or decrease appropriately depending on age and symptoms.
4. Patients with renal impairment: The administration interval should be adjusted according to the patient's renal function. Adjust the dosage by referring to the following table. To use this dosage table, you need the creatinine clearance (CLcr) in mL/min. CLcr (mL/min) is calculated from serum creatinine (mg/dL) measurements using the formula:
: CLcr = [140 - age (age) (years)] x weight (kg) / 72 x serum creatinine (mg/dL) (x0.85 for women)
<Dosage adjustment for adult patients with impaired renal function>
※ Please check the attached document for details.
For pediatric patients with renal impairment (renal impairment), the dose should be adjusted individually, taking into account the patient's renal clearance and body weight.
4. Precautions for use
1. The following people should not take (use) this medicine:
1) Patients with a history of hypersensitivity to this drug and hydroxyzine or piperazine derivatives
2) Patients with renal failure (creatinine clearance < 10mL/min)
3) Pregnant women, women who may be pregnant, or lactating women
4) Infants under 6 years of age
5) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. (Limited to products containing lactose)
2. Do not take (use) the following medicines while taking (using) this medicine.
1) In a multiple-dose study of theophylline (400 mg once daily) and cetirizine, the pharmacokinetics of theophylline did not change when administered together with cetirizine, while the clearance of cetirizine decreased slightly (16%).
2) In a multiple-dose study of ritonavir (600 mg, twice daily) and cetirizine (10 mg daily), the breakdown of ritonavir was slightly changed (-11%) when administered together with cetirizine, while the exposure to cetirizine increased by approximately 40%.
3. Do not do the following while taking (using) this medicine.
1) As this drug is secreted in small amounts through breast milk, breast-feeding should be discontinued during administration.
2) As with other antihistamines, do not administer with excessive amounts of alcohol.
4. The following people should consult a doctor, dentist, or pharmacist before taking (using) this medicine.
1) Patients with renal impairment (high blood levels may persist)
2) Patients with hepatic impairment (high blood levels may persist)
3) Elderly (high blood levels may persist)
This drug is mainly excreted through the kidneys, so in elderly people with reduced renal function, excessive blood concentration may persist. Therefore, start administration with caution at a low dose, and if abnormalities are recognized, reduce the dose or stop taking the drug and take appropriate measures.
4) Epilepsy patients and patients at risk of seizures
5) This drug may increase the risk of urinary retention, so caution should be exercised when using it in patients with predisposing factors for urinary retention (e.g. spinal cord lesions, prostatic hyperplasia).
5. In the following cases, immediately stop taking (using) this drug and consult a doctor, dentist, or pharmacist. Please carry this attached document with you whenever possible during consultation.
1) Symptoms and treatment in case of overdose
- Symptoms: Symptoms observed after overdose of cetirizine are mainly related to central nervous system effects or effects considered to be anticholinergic. Adverse reactions reported after taking at least 5 times the recommended daily dose include: confusion, diarrhea, dizziness, fatigue, headache, malaise, dilated pupils, itching, nervousness, sedation, drowsiness, stupor, tachycardia, tremors, and urine retention.
- Treatment: There is no known specific antidote for cetirizine. If an overdose of this drug is administered, symptomatic treatment or supportive treatment is recommended. If it has only recently been taken, gastric lavage should be considered.
Cetirizine is not effectively removed by dialysis.
2) Mental nervous system: Drowsiness, headache, sometimes malaise, paralysis, asthenia, nervousness, paresthesia, rarely mild and temporary drowsiness, fatigue, dizziness, heaviness in the head, excitement, convulsions, dyskinesia, dystonia, syncope, tremors, aggression, confusion, depression, hallucinations, insomnia, tic disorder, amnesia, memory impairment, suicidal ideation, and nightmares may occur.
3) Digestive system: Sometimes thirst, dry lips, nausea, loss of appetite, stomach discomfort, indigestion, abdominal pain, stomach pain, abdominal discomfort, diarrhea, rarely vomiting, gastrointestinal disorders, cheilitis, abnormal taste, and increased appetite may occur.
4) Circulatory system: In rare cases, rapid pulse, arrhythmia, increased blood pressure, and sometimes palpitations may occur.
5) Blood: Vasculitis, sometimes a decrease in white blood cells, a decrease in neutrophils, an increase in lymphocytes, an increase in eosinophils, rarely an increase in monocytes, and an increase in platelets may occur. In addition, since thrombocytopenia may rarely occur, sufficient observation should be conducted, and if abnormalities are recognized, administration should be discontinued and appropriate measures should be taken.
6) Immune system, skin and subcutaneous tissue: Photosensitivity, rarely hypersensitivity and anaphylactic shock, sometimes swelling, itching, rash, rarely urticaria, angioneurotic edema, fixed drug rash, and acute generalized rash and pustulosis may occur.
7) Eyes: In rare cases, blurred vision, conjunctival injection, ocular control disorders, and anterior-posterior eye movements (oculogyration) may occur.
8) Ear and Maze: Vertigo
9) Liver: Occasionally, liver dysfunction such as elevation of AST, ALT, ALP, total bilirubin, γ-GTP, LDH, etc. (early symptoms: general malaise, loss of appetite, fever, nausea, etc.), jaundice, and hepatitis may occur. Therefore, observe thoroughly, and if abnormalities are recognized, discontinue administration and take appropriate measures.
10) Kidney: Occasionally, BUN elevation, diabetes, bloody urine, rare urination difficulties, enuresis, and urine retention may occur.
11) Musculoskeletal and connective tissue disorders: joint pain
12) Others: Pharyngitis, cough, nosebleeds, bronchospasm, hearing abnormalities, visual abnormalities, sometimes chest pain, rarely menstrual irregularities, tinnitus, rhinitis, and weight gain may occur.
13) After cetirizine treatment was discontinued, itching and/or hives were reported in some patients.
6. Other precautions when taking (using) this drug
1) Since this drug inhibits the intradermal reaction to allergens, it is advisable not to administer this drug 3 to 5 days before conducting an allergen intradermal reaction test.
2) As a result of administering 20 to 25 mg per day to healthy volunteers, no side effects were observed in agility or reaction time, but the dose was not exceeded when driving or operating machinery. Although the racemate (enantiomer) does not appear to increase the effects of alcohol (0.5 g/L blood level), coadministration of alcohol or other CNS depressants may further reduce alertness and cause performance impairment.
3) Depending on the symptoms, if there is no improvement with the administration of 10 mg of this drug per day, there are clinical reports of administering up to 20 mg per day according to the instructions of a doctor or pharmacist.
4) The absorption rate of cetirizine is reduced by food for about 1 hour, but the degree of absorption is not reduced.
7. Storage precautions
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause an accident due to incorrect use of the medicine or cause a decrease in the quality of the medicine, so put it in the original container and keep it tightly closed.
5. How to save
Airtight container, stored at room temperature (1∼30℃)
6. Packaging unit
10 tablets/PTP
7. Validity period
36 months from date of manufacture
Product Updates
Total 4items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 4 | Cozoltec Tab. | Precautions for use | 2024.11.29 | PDFCetirizine hydrochloride single agent (film-coated tablet) unification adjustment (draft) (draft change).pdf |
| 3 | Cozoltec Tab. | Indications, Dosage and Administration, and Precautions for Use | 2021.01.14 | HWPPermission change order and change comparison table_Cetirizine hydrochloride single agent (tablet).hwp |
| 2 | Cozoltec Tab. | Kozoltec tablets (precautions for use) | 2017.08.01 | HWPCetirizine hydrochloride single oral tablets and capsules unified adjustment plan. |
| 1 | Cozoltec Tab. | Kozoltec tablets (precautions for use) | 2015.04.28 | HWPCetirizine hydrochloride_single oral administration_tablets, capsules_unified adjustment plan.h |